Genetically Proxied Therapeutic Effect of Lipid-Lowering Drugs Use, Breast Cancer, and Endometrial Cancer's Risk: A Drug Target-Based Mendelian Randomization Study
Chunxiao Dang,Xiaofeng Wang,Pengfei Liu,Jinxing Liu,Xiao Yu
DOI: https://doi.org/10.2147/ijwh.s468733
2024-11-29
International Journal of Women s Health
Abstract:Chunxiao Dang, 1, &ast Xiaofeng Wang, 2, &ast Pengfei Liu, 1 Jinxing Liu, 1 Xiao Yu 3 1 First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People's Republic of China; 2 Dongying People's Hospital (Dongying Hospital of Shandong Provincial Hospital Group), Dongying, Shandong, People's Republic of China; 3 Department of Gynecology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiao Yu, Affiliated Hospital of Shandong University of Traditional Chinese Medicine Affiliated Hospital, Lixia District, Jinan City, Shandong Province, People's Republic of China, Tel +8615969675751, Email Jinxing Liu, Shandong University of Traditional Chinese Medicine, Lixia District, Jinan City, Shandong Province, People's Republic of China, Tel +8615966696662, Email Background: Observational studies have investigated the association between lipid-lowering drugs and breast cancer (BC) and endometrial cancer (EC), but some controversy remains. Objective: This paper aims to explore the causal relationship between genetic proxies for lipid-lowering drugs and breast and endometrial cancers using drug-target Mendelian randomization (MR). Methods: Analyses were mainly performed using inverse variance weighted (IVW), heterogeneity and horizontal pleiotropy tests, and sensitivity analysis to assess the robustness of the results and causal relationship. Results: HMGCR, APOB, and NPC1L1 increased the risk of breast cancer, LPL increased the risk of endometrial cancer, and APOC3 decreased the risk of breast and endometrial cancer. No heterogeneity or horizontal pleiotropy was detected, and nor was there any evidence of an association between other lipid-lowering drugs and breast and endometrial cancer. Conclusion: Our study demonstrated genetically that HMGCR inhibition, APOB inhibition, and NPC1L1 inhibition decrease the risk of breast cancer, LPL agonist increases the risk of endometrial cancer, and APOC3 inhibition decreases the risk of breast cancer and endometrial cancer, and these findings provide genetic insights into the potential risks of lipid-lowering drug therapy. Keywords: lipid-lowering drugs, breast cancer, endometrial cancer, drug-target Mendelian randomization Breast cancer (BC) is the most common malignancy among women worldwide and the annual incidence continues to increase. 1 According to the 2020 estimates by International Agency for Research on Cancer (IARC), female breast cancer has surpassed lung cancer as the leading cause of cancer incidence worldwide, with approximately 2.3 million new cases, accounting for 11.7% of all cancer cases. 2 Endometrial cancer (EC) is the seventh most common malignant disease in the world and the most common gynecological malignancy in developed countries. 3 Although 75% of patients with EC can be diagnosed at an early stage, the prognosis of patients with advanced disease remains poor. 4 Due to limited therapeutic measures (eg, surgery, radiotherapy, and hormonal therapy) and the poor prognosis of BC & EC, 5,6 primary prevention may become the least costly strategy for controlling BC & EC, which can effectively reduce the burden of the disease. Reprogramming of lipid metabolism is one of the hallmarks of cancer, 7,8 and cholesterol, an important component of blood lipids, is thought to underlie the proliferation and survival of cancer cells. 9 Several studies have shown a negative correlation between serum cholesterol levels and cancer risk. 10 Cholesterol is thought to increase the risk of BC & EC because it is a precursor for steroid hormone synthesis and endogenous steroid hormones, which are directly associated with BC risk. 11,12 Dyslipidaemia is characterized by elevated levels of triglycerides (TG), small and dense low-density lipoprotein cholesterol (LDL-C), as well as reduced levels of high-density lipoprotein cholesterol (HDL-C). 13 Higher levels of TG, HDL-C, and lower levels of LDL-C have been found to be associated with a reduced risk of BC, while higher levels of TG and HDL-C have been associated with an increased risk of EC. 14–16 Recent studies 17,18 have confirmed the close relationship between dyslipidaemia and BC & EC, and there is also increasing interest in the role of lipid-lowering drugs in BC & EC. Evidence from preclinical studies suggests that statins may have anticancer properties by inducing apoptosis and inhib -Abstract Truncated-
obstetrics & gynecology